Cardiff Oncology, Inc.

NasdaqCM:CRDF Aktierapport

Börsvärde: US$59.8m

Cardiff Oncology Förvaltning

Förvaltning kriterier kontrolleras 2/4

Cardiff Oncology VD är Mani Mohindru, utsedd i Jan 2026, har en anställningstid på mindre än ett år. äger direkt 0.036% av företagets aktier, värda $ 21.60K. Den genomsnittliga mandatperioden för ledningsgruppen och styrelsen är 0.5 år respektive 11.9 år.

Viktig information

Mani Mohindru

Verkställande direktör

US$183.7k

Total ersättning

VD-lön i procentn/a
Anställning som VDless than a year
Ägande av VD0.04%
Ledningens genomsnittliga anställningstidless than a year
Styrelsens genomsnittliga mandatperiod11.9yrs

Senaste uppdateringar av ledningen

Recent updates

Seeking Alpha • Jun 27

Cardiff Oncology: Delayed Trial Data Update Unnerves Investors But Gives Bulls A Final Buy Low Opportunity

Summary Cardiff Oncology's recent trial data readout delay has unnerved the market, but I see this as a potential buying opportunity for speculative investors. Leadership change is not a major risk factor. The new CMO's pedigree suggests confidence in the company's prospects ahead of the catalyst. The delay could suggest an attempt to improve poor data, or an ability to add to already strong data by waiting for more patient second scans. Short interest is high, increasing volatility and squeeze potential if trial data is strong, but also signaling caution from sophisticated investors. CRDF's cash runway is sufficient for the near-term catalyst; I hold call options expecting momentum to return, as the July 29th readout date approaches. Read the full article on Seeking Alpha
Analysartikel • May 21

Is Cardiff Oncology (NASDAQ:CRDF) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Feb 18

Cardiff Oncology: Pioneering RAS-Mutated Cancer Therapies With Onvansertib

Summary Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC, with a strong therapeutic profile and potential for high returns if approved. Onvansertib's Phase II results indicate superior efficacy in first-line treatment, supporting Cardiff's financial stability and long-term investment potential. The competitive landscape includes therapies like LUMAKRAS and KRAZATI, but Onvansertib's mutation-agnostic approach offers a unique advantage. Despite high risks, Cardiff's cash runway and positive clinical data justify a "Strong Buy" rating for high-risk tolerant long-term investors. Read the full article on Seeking Alpha
Seeking Alpha • Dec 12

Cardiff Oncology: The Long-Awaited First-Line MCRC Data Are Here, But The Work Is Just Beginning

Summary Cardiff Oncology's phase 2 trial of onvansertib in mCRC shows promising preliminary data, with improved response rates in a dose-dependent manner. Onvansertib appears well tolerated and effective when combined with standard chemotherapy and bevacizumab, but patient numbers remain low, necessitating further validation. Financially, CRDF's equity raise extends their cash runway, supporting the continued development and reducing immediate financial risk. Despite uncertainties, I maintain a Buy rating, anticipating onvansertib's potential to significantly impact first-line RAS-mutant mCRC therapy. Read the full article on Seeking Alpha
Seeking Alpha • Nov 07

Cardiff Oncology: Some Data Are In; Here's What You Should Know And Look For Next

Summary Cardiff Oncology's main focus is onvansertib, a PLK1 inhibitor, showing promise in metastatic colorectal cancer, especially in bevacizumab-naive patients. CRDF-004 phase 2 trial's results are crucial for Cardiff's future, with data expected within two months, potentially informing a pivotal phase 3 trial. Financially, Cardiff has a cash runway of 5-6 quarters, but will need additional funding, potentially leading to significant shareholder dilution. While optimistic about onvansertib's potential, I caution investors due to the high-risk nature and uncertain outcomes of the upcoming trial results. Read the full article on Seeking Alpha
Analysartikel • Oct 09

We're Keeping An Eye On Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Oct 04

Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market

Summary Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated metastatic colorectal cancer, potentially opening a massive market with an estimated $567 million to $3.78 billion in annual US sales. Onvansertib has demonstrated superior efficacy and safety over historical controls and competitors, particularly in bevacizumab-naïve patients, with impressive objective response rates and progression-free survival. Positive data from the ongoing CRDF-004 trial could lead to significant upside for Cardiff, attracting potential partnerships or acquisition interest from big pharma, including Pfizer. Cardiff's strong financial position, low cash burn, and favorable analyst ratings make it a compelling buy, with substantial growth potential in the mCRC market and beyond. Read the full article on Seeking Alpha
Analysartikel • Jun 19

We're Hopeful That Cardiff Oncology (NASDAQ:CRDF) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Mar 09

Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)

Summary Cardiff Oncology is focused on developing a drug for colorectal cancer and pancreatic cancer, with promising early activity shown in colorectal cancer patients. The company is now focused on moving their drug to the first-line setting and has started a clinical trial to evaluate its efficacy. Cardiff Oncology has a strong financial position with enough funds to operate through Q3 2025, but the success of their drug is heavily dependent on the outcomes of a single trial. Read the full article on Seeking Alpha
Analysartikel • Mar 03

We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysartikel • Nov 16

Here's Why We're Watching Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

VD OCH KONCERNCHEF

Mani Mohindru (54 yo)

less than a year
Anställning
US$183,670
Kompensation

Dr. Mani Mohindru, Ph D., is Co-Founder, President and Director of Roshon Therapeutics. She had been Interim Chief Executive Officer at Cardiff Oncology, Inc. since January 27, 2026 until April 09, 2026 an...

Ledningsgrupp

NamnPositionAnställningKompensationÄgarskap
Mani Mohindru
Presidentless than a yearUS$183.67k0.036%
$ 21.6k
Roger Sidhu
Chief Medical Officer1.1yrsUS$2.47m0%
$ 0
Josh Muntner
Chief Financial Officerless than a yearinga uppgifter0.00073%
$ 436.5
Ajay Aggarwal
Chief Operating Officerless than a yearinga uppgifteringa uppgifter
Brigitte Lindsay
Chief Accounting Officerless than a yearinga uppgifter0.040%
$ 24.0k
Tod Smeal
Chief Scientific Officer4.5yrsUS$4.17minga uppgifter
Elizabeth Anderson
VP of Finance & Administration11yrsinga uppgifteringa uppgifter
0.5yrs
Genomsnittlig anställningstid
57yo
Genomsnittlig ålder

Erfaren ledning: CRDF s ledningsgrupp anses inte vara erfaren ( 0.5 års genomsnittlig anställningstid), vilket föreslår ett nytt team.

Styrelseledamöter

NamnPositionAnställningKompensationÄgarskap
Mani Mohindru
President5.1yrsUS$183.67k0.036%
$ 21.6k
Charles Cantor
Member of Scientific Advisory Boardno datainga uppgifteringa uppgifter
Gary Pace
Independent Director6.3yrsUS$184.17k2.02%
$ 1.2m
K. Hirth
Member of Scientific Advisory Board11.9yrsinga uppgifteringa uppgifter
Paul Billings
Member of Scientific Advisory Board13.7yrsUS$35.85kinga uppgifter
Rodney Markin
Independent Chairman of the Board12.4yrsUS$225.67k0.045%
$ 27.2k
Carlo Croce
Member of Scientific Advisory Boardno datainga uppgifteringa uppgifter
Riccardo Dalla-Favera
Member of Scientific Advisory Board16.3yrsinga uppgifteringa uppgifter
Lale White
Independent Director6.3yrsUS$189.17k0.17%
$ 99.5k
Alberto Bardelli
Member of Scientific Advisory Board11.8yrsinga uppgifteringa uppgifter
Renee Tannenbaum
Independent Director5.1yrsUS$181.67k0.029%
$ 17.5k
Brunangelo Falini
Member of Scientific Advisory Board16.3yrsinga uppgifteringa uppgifter
11.9yrs
Genomsnittlig anställningstid
74yo
Genomsnittlig ålder

Erfaren styrelse: CRDF s styrelse är rutinerade och erfaren ( 11.9 års genomsnittlig mandatperiod).

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2026/07/17 10:41
Aktiekurs vid dagens slut2026/07/17 00:00
Intäkter2026/03/31
Årlig intjäning2025/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Cardiff Oncology, Inc. bevakas av 14 analytiker. 9 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Paul KnightBrean Capital Historical (Janney Montgomery)
Bryan BrokmeierCantor Fitzgerald & Co.
Gum-Ming LoweCraig-Hallum Capital Group LLC